NeoDynamics Partners with Uniphar for US Distribution and Logistics

NeoDynamics AB (Nasdaq First North Growth Market Stockholm: NEOD.ST), a medical device company dedicated to advancing the diagnosis and care of cancer, today announced it is partnering with global distribution and logistics giant Uniphar Group to ensure a successful US launch of NeoNavia®, its innovative pulse biopsy system.

“NeoDynamics couldn't be more pleased to be partnering with Uniphar, a proven global partner to pharma and MedTech companies.  Leveraging Uniphar’s customer service, logistics management and digital technology will allow us to aggressively hit the US market,” said Anna Eriksrud CEO of NeoDynamics. “The relationship with Uniphar is a key corporate development as we put all the pieces in place for the successful US launch of NeoNavia.”

Rick Hughes, Managing Director of Uniphar Logistics, said “As Uniphar MedTech continues its expansion into North America in pursuit of end-to-end supply chain solutions for its customers, we are pleased to partner with NeoDynamics for patient support through Diligent Healthcare, a Uniphar company, in addition to medical device distribution through Uniphar Logistics.”

Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. The Group is active in Ireland, the UK, Europe, the US and Australia.

In anticipation of our US launch, NeoDynamics has put in place an experienced senior management team. Adding Uniphar Logistics is another component of the commercialization support infrastructure.  Once completed we will begin assembling the US sales organization.  We expect our first interaction with US customers will occur at the annual conference of the American Society of Breast Cancer Surgeons in April.

For further information, please contact:

Anna Eriksrud, CEO NeoDynamics AB +46708 444 966 or e-mail anna.eriksrud@neodynamics.com

Aaron Wong, CFO NeoDynamics AB +46 735 972 011 or e-mail aaron.wong@neodynamics.com

Pernille Friis Andersen, +45 3093 1887 or e-mail Pernille@hcandersencapital.dk

Claus Thestrup, +46 707 553 057 or e-mail claus@hcandersencapital.dk

Tim Ryan, US Investor Relations, +1 646.342.6199 or e-mail tryan@shorehamgroupllc.com

About NeoDynamics

NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and will soon launch in the USA. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.

About NeoNavia

NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

About Karolinska Institute

The Karolinska Institute is consistently ranked amongst the world's best medical schools, ranking 6th worldwide for medicine in 2021. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine.